Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer ...

Pfizer delivered a strong Q2 2025, beating revenue and EPS estimates, raising EPS guidance, and maintaining its attractive dividend yield above 7%. Product portfolio strength is evident, with growth ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial guidance (5) provided on December 17, 2024. The ...

Novo Nordisk NVO and Pfizer PFE are pharmaceutical giants based in Denmark and the United States, respectively, with strong ...

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about a year. This time, the drug that delivered the positive readout is Tukysa, ...

Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma company’s aging blockbusters. Late Friday, after a dramatic bidding war, he ...